Pan-cancer landscape of CD274 (PD-L1) rearrangements in 283,050 patient samples, its correlation with PD-L1 protein expression, and immunotherapy response

BACKGROUND: Immune checkpoint inhibitors (ICIs) benefit patients with multiple cancer types, however, additional predictive biomarkers of response are needed. CD274 (programmed cell death ligand-1, PD-L1) gene rearrangements are positively associated with PD-L1 expression and may confer benefit to I...

Descripción completa

Detalles Bibliográficos
Autores principales: Kelly, Andrew D, Murugesan, Karthikeyan, Kuang, Zheng, Montesion, Meagan, Ross, Jeffrey S, Albacker, Lee A, Huang, Richard S P, Lin, Douglas I, Demirci, Umut, Creeden, James
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2021
Materias:
Immunotherapy Biomarkers
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8611421/
https://www.ncbi.nlm.nih.gov/pubmed/34815356
http://dx.doi.org/10.1136/jitc-2021-003550

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8611421/
https://www.ncbi.nlm.nih.gov/pubmed/34815356
http://dx.doi.org/10.1136/jitc-2021-003550

Ejemplares similares